Semaglutide is now approved for T2D patients with CKD, reducing cardiovascular and kidney disease risks. The FLOW phase 3b trial showed significant reductions in adverse kidney and cardiovascular ...
Official data shows that since 2019, this medication has been linked to 23 deaths and 1,179 serious adverse reactions in the ...